Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.48% | -21.90% | -21.58% | -27.92% | -45.48% |
| Total Depreciation and Amortization | 24.21% | -59.50% | 29.20% | 43.95% | 26.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.56% | 186.97% | 58.44% | 23.28% | -10.30% |
| Change in Net Operating Assets | -3.20% | -54.73% | -89.12% | -128.52% | 973.08% |
| Cash from Operations | -20.04% | -9.41% | -21.85% | -39.74% | -53.52% |
| Capital Expenditure | 45.26% | 67.49% | 53.99% | 26.37% | -94.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 258.91% | -240.84% | 29.28% | -2.56% | 63.92% |
| Cash from Investing | 248.13% | -251.92% | 30.20% | -1.85% | 62.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.57% | 997.83% | 50,044.96% | 30.65% | 26.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.57% | 997.83% | 50,044.96% | 30.65% | 26.95% |
| Foreign Exchange rate Adjustments | -544.68% | -128.50% | 58.32% | 98.16% | 115.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.49% | -205.31% | 123.63% | 77.43% | 177.17% |